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We propose a new mechanism to explain autoinhibition of the epidermal growth factor receptor (EGFR/ErbB)
family of receptor tyrosine kinases based on a structural model that postulates both their juxtamembrane and
protein tyrosine kinase domains bind electrostatically to acidic lipids in the plasma membrane, restricting access of
the kinase domain to substrate tyrosines. Ligand-induced dimerization promotes partial trans autophosphorylation
of ErbB1, leading to a rapid rise in intracellular [Ca
 
2
 
 
 
] that can activate calmodulin. We postulate the Ca
 
2
 
 
 
/
calmodulin complex binds rapidly to residues 645–660 of the juxtamembrane domain, reversing its net charge
from 
 
 
 
8 to 
 
 
 
8 and repelling it from the negatively charged inner leaﬂet of the membrane. The repulsion has two
consequences: it releases electrostatically sequestered phosphatidylinositol 4,5-bisphosphate (PIP
 
2
 
), and it disengages
the kinase domain from the membrane, allowing it to become fully active and phosphorylate an adjacent ErbB
molecule or other substrate. We tested various aspects of the model by measuring ErbB juxtamembrane peptide
binding to phospholipid vesicles using both a centrifugation assay and ﬂuorescence correlation spectroscopy;
analyzing the kinetics of interactions between ErbB peptides, membranes, and Ca
 
2
 
 
 
/calmodulin using ﬂuorescence
stop ﬂow; assessing ErbB1 activation in Cos1 cells; measuring ﬂuorescence resonance energy transfer between
ErbB peptides and PIP
 
2
 
; and making theoretical electrostatic calculations on atomic models of membranes and
ErbB juxtamembrane and kinase domains.
 
INTRODUCTION
 
The general mechanism by which binding of a ligand to
the extracellular domain of a typical receptor tyrosine
kinase activates its intracellular protein tyrosine kinase
(PTK) domain is well understood: binding produces
dimerization (or dimer rearrangement) that leads to
trans autophosphorylation of tyrosines in the “activation
loop” of the PTK domain (Hubbard and Till, 2000;
Schlessinger, 2000, 2003; Huse and Kuriyan, 2002;
Jorissen et al., 2003; Hubbard, 2004). The ErbB tyrosine
kinase family (ErbB1/HER1/EGFR, ErbB2/HER2,
ErbB3/HER3, ErbB4/HER4) appears to be the major
exception to this rule because their PTK domains do
not require phosphorylation for catalytic competency
(Gotoh et al., 1992; Jorissen et al., 2003; Hubbard,
2004). The structure of the ErbB1 PTK domain suggests
why this is so: the unphosphorylated activation loop is in
an active conformation and the catalytic elements are
“primed and ready for phospho-transfer,” suggesting
“the regulation of the vital cellular processes inﬂuenced
by epidermal growth factor receptor (EGFR) signaling
must be exerted by control of the delivery of the
COOH-terminal substrate tyrosines to the active site”
(Stamos et al., 2002). Understanding this control
mechanism is important because members of the ErbB
family are frequently overactive in solid tumors (Blume-
Jensen and Hunter, 2001; Yarden and Sliwkowski, 2001;
Gschwind et al., 2004; Paez et al., 2004; Sordella et al.,
2004); ErbB2, for example, is overexpressed in 25% of
breast cancers, and this overexpression correlates with
poor prognosis (Klapper et al., 2000).
Several groups have recently proposed models to
explain autoinhibition of the ErbB family. Landau et
al. (2004) developed a computational model that
suggests direct contact between a positively charged
face of the kinase domain and a negatively charged
segment of the COOH-terminal tail region of the re-
ceptor produces autoinhibition. Alternatively, Aifa et
al. (2005) proposed that this negatively charged seg-
ment, ErbB1(979–991), interacts with a cluster of basic
residues in the juxtamembrane (JM) region of an adja-
cent ErbB molecule. The ErbB1 basic JM region also
plays an important role in the structural model of auto-
inhibition we propose.
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2
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In our model, basic residues in the ErbB JM and PTK
domains interact electrostatically with acidic lipids in
the membrane, inhibiting catalytic activity in the ab-
sence of ligand. This autoinhibitory hypothesis has an
obvious corollary: conditions that decrease the electro-
static binding (e.g., an increase in the cytoplasmic salt
concentration, exposure to an amphipathic weak base
that decreases the negative ﬁxed charge density on the
membrane) should release the JM and PTK regions
from the membrane, producing ligand-independent
trans autophosphorylation. We have tested this corol-
lary by comparing data from our experiments with
model membranes and peptides to data in the litera-
ture from intact cells.
Our model also suggests a novel positive feedback
mechanism by which ligand-induced dimerization may
contribute to activation. As discussed below, it is well es-
tablished that ligand-induced dimerization of ErbB1
leads to a transient (
 
 
 
10 min) increase in the level of
free Ca
 
2
 
 
 
 within a cell. We postulate that calcium/cal-
modulin (Ca/CaM) binds to the ErbB JM region very
rapidly (
 
 
 
100 ms when [Ca/CaM] 
 
 
 
 1 
 
 
 
M), reversing
its charge and repelling both it and the PTK domain
from the membrane. This implies Ca/CaM binding will
increase the initial rate of trans autophosphorylation
over and above the rate due to the local concentration
effect resulting from ligand-induced dimerization. Our
postulated Ca/CaM-mediated activation mechanism
will be important only when the [Ca
 
2
 
 
 
] is high enough
to produce a signiﬁcant increase in Ca/CaM.
The model predicts that Ca/CaM can pull peptides
corresponding to the ErbB JM region off a membrane
rapidly and that CaM inhibitors will inhibit, but not
completely block, the initial phase of EGF-mediated
ErbB autophosphorylation in cells. We tested these pre-
dictions experimentally; while the results are consistent
with the predictions, they neither prove that the model
is correct nor rule out other potential activation mech-
anisms that may act in parallel (Jorissen et al., 2003;
Schlessinger, 2003). For example, there is much evi-
dence that phosphatases play an important role in con-
trolling the trans autophosphorylation of ErbB (e.g.,
Reynolds et al., 2003; Tonks, 2003; Ichinos et al., 2004;
Matilla et al., 2004); we return to the role of phos-
phatases in the concluding section of DISCUSSION.
 
Structural Model
 
Fig. 1 illustrates our model; the cartoons (Fig. 1, A and
B) focus on the 
 
 
 
40-residue JM domain (residues 645–
682 in ErbB1) between the helical transmembrane
(TM) and structured PTK domains. Fig. 1 C shows the
sequence of the ErbB1 JM domain using color coding
to indicate the amino acids that can interact with the
bilayer: basic (R and K) residues are blue, acidic resi-
dues (E) are red, and hydrophobic residues (F, L, I,
and V) are green. The cytoplasmic leaﬂet of a mamma-
Figure 1. Model of ErbB
activation.  (A) ErbB1 in a
quiescent cell (no EGF, low
free [Ca2 ] in cytosol). The
cytoplasmic leaﬂet of the
plasma membrane contains
acidic phospholipids (lipids
with red minus signs) that
strongly attract the reversible
membrane anchor region of
the JM domain, comprising
eight basic (circled blue plus
signs) and ﬁve hydrophobic
residues (green circles). The
PTK core (depicted with the
COOH-terminal portion of
the JM domain as a rectangle
of appropriate dimensions,
5    6 nm) has a positively
charged face (blue plus signs)
that also binds electrostati-
cally to the bilayer. We postu-
late that these membrane
interactions inhibit the enzyme. The length of the ﬁrst two portions of the JM domain, as well as the size of the PTK domain and calcium/
calmodulin (Ca/CaM), are drawn approximately to scale with the bilayer (thickness  5 nm). (B) Activated ErbB1. After ligand-induced
dimerization (not depicted) and partial trans autophosphorylation, we postulate that binding of acidic Ca/CaM (charge    16) to the
basic (charge    8) reversible membrane anchor forms a high afﬁnity complex with a net charge of –8; this charge reversal repels the
complex from the negatively charged bilayer, ripping both the JM and PTK domains off the membrane and fully activating the ErbB1. The
PTK core is now free to rotate via the ﬂexible linker, giving the catalytic site access to tyrosines on an adjacent ErbB family member
(not depicted), or other substrate. As discussed in the text, Ca/CaM may cycle on and off the JM region at up to a diffusion limited rate
( 102 s 1 if [Ca/CaM]   10 6 M). (C) Sequence of the JM region of ErbB1. SwissProt accession no. P00533. 
McLaughlin et al. 43
 
lian cell plasma membrane typically contains 15–30%
monovalent acidic phospholipid, mainly phosphati-
dylserine (PS), which produces a negative surface po-
tential of 
 
 
 
30 to 
 
 
 
40 mV (McLaughlin, 1989). Hence
the membrane bilayer attracts blue and green residues
through electrostatic and hydrophobic interactions, re-
spectively, and electrostatically repels red residues.
We divide the JM domain into three sections (Fig. 1
C) and hypothesize that the 16-residue NH
 
2
 
-terminal
region (Arg645 to Gln660 of ErbB1) acts as a reversible
membrane anchor. Speciﬁcally, we follow the sugges-
tions of Ullrich et al. (1984) and Hunter et al. (1984)
and postulate that in a quiescent cell, i.e., when no
ligands are present and the free [Ca
 
2
 
 
 
] is low, the eight
basic and ﬁve hydrophobic amino acids bind this re-
gion to the negatively charged inner leaﬂet of the
bilayer. In our model, the 12-residue central region
(Glu661 to Gly672 of ErbB1) acts as a ﬂexible linker
that joins the reversible membrane anchor to the
COOH-terminal section of the JM domain. The ﬂexible
linker has a net charge of 
 
 
 
2 (3 E, 1R); it should be re-
pelled, albeit weakly, from the membrane bilayer. The
10-residue COOH-terminal region of the JM domain
(Glu673 to Ile682) was identiﬁed in the structure of the
ErbB1 PTK core (Stamos et al., 2002). Fig. 2 illustrates
that one face of this COOH-terminal JM region 
 
 
 
 PTK
structure is positively charged (blue), and thus should
bind electrostatically to the negatively charged bilayer,
as drawn in Fig. 1 A. Fig. 2 also shows that the PTK do-
main has a strong dipole character (i.e., one face is pos-
itive, while the remainder of the molecule surface is
mainly negative); thus it will not be free to rotate when
bound to the bilayer. A key assumption of our model is
that binding of the PTK core to the membrane inhibits
its activity; hindered rotation could, for example, limit
its contact with, and thus ability to phosphorylate, ty-
rosines in the COOH-terminal tail of an ErbB family
dimer or other substrate.
Under physiological conditions, a ligand such as EGF
binds to the ErbB1 extracellular domain and induces
dimerization. Recent structural studies of the ErbB1 ex-
tracellular domain with (Ogiso et al., 2002) and with-
out (Ferguson et al., 2003) bound EGF indicate that
ligand binding triggers a dramatic rearrangement of
the four extracellular subdomains in each receptor
monomer. A direct intramolecular interaction between
cysteine-rich subdomains II and IV in the unactivated
receptor is broken upon EGF binding, and loss of con-
tact releases a dimerization arm on domain II that me-
diates direct ErbB1 monomer–monomer contacts (for
reviews see Burgess et al., 2003; Ferguson, 2004).
In our model, the intracellular JM 
 
 
 
 PTK regions of
each dimer pair exist in equilibrium between the mem-
brane-bound (Fig. 1 A) and free (not shown) states,
with the autoinhibited membrane-bound state predom-
inating in the absence of Ca/CaM. Upon ErbB dimer-
ization (not depicted in Fig. 1 for simplicity), the small
fraction of dimeric receptors with membrane-free JM 
 
 
 
PTK regions can trans autophosphorylate. Phosphory-
lation of tyrosine residues in the ErbB COOH-terminal
tail leads to binding and activation of PLC-
 
 
 
, hydrolysis
of phosphatidylinositol 4,5-bisphosphate (PIP
 
2
 
) with
concomitant production of inositiol 1,4,5-trisphos-
phate (IP
 
3
 
), and IP
 
3
 
-mediated release of Ca
 
2
 
 
 
 from in-
ternal stores (for review see Jorissen et al., 2003). The
transitory release of Ca
 
2
 
 
 
 from intracellular stores me-
diated by IP
 
3
 
 is followed by a more sustained inﬂux of
Ca
 
2
 
 
 
 across the plasma membrane (e.g., Pandiella et
al., 1988; Cheyette and Gross, 1991; Hughes et al.,
1991; Bezzerides et al., 2004; Li et al., 2004c). Adding
30 nM EGF to A431 cells, for example, increases intra-
cellular [Ca
 
2
 
 
 
] about ﬁvefold, to 600 nM, in 
 
 
 
5 min;
[Ca
 
2
 
 
 
] then declines over 
 
 
 
10 min to a value only
slightly above the basal level (Hughes et al., 1991).
The EGF-mediated transient increase in cytoplasmic
[Ca
 
2
 
 
 
] activates CaM, and our data, together with pre-
vious work on peptides (Martin-Nieto and Villalobo,
1998) and native ErbB1 (Li et al., 2004a), suggest the
Ca/CaM complex can bind rapidly and strongly to resi-
dues 645–660 of ErbB1, as shown in Fig. 1 B. This bind-
ing reverses the charge on the region from 
 
 
 
8 to 
 
 
 
8,
converting its strong electrostatic attraction to the
membrane into a strong electrostatic repulsion. We hy-
pothesize that the binding energy of Ca/CaM for the
reversible membrane anchor region and the electro-
static repulsion of the resulting complex from the neg-
Figure 2. Electrostatic potential proﬁle adjacent
to the ErbB1 PTK core. The red and blue meshes
illustrate the  25 and  25 mV equipotential proﬁles,
respectively. Potentials calculated from the Poisson-
Boltzmann equation in 100 mM salt and illustrated
using GRASP. (A) ErbB1 PTK (together with residues
673–682 of the JM) domain, as revealed by the crystal
structure (Stamos et al., 2002). The orientation is the
same as depicted in Fig. 1 A; the membrane is above
the basic (blue) face. (B) Structure rotated 90  to
show the positively charged face. Residues 673–682
are the extended region at the top of the structure,
starting from N. 
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atively charged bilayer provide the energy to move the
PTK core of an ErbB family member off the bilayer.
Thus we refer to this mechanism as an “electrostatic en-
gine” that increases both the frequency at which the
JM 
 
 
 
 PTK domain moves from its autoinhibitory mem-
brane-bound conformation (Fig. 1 A) to a freely rotat-
ing active state (Fig. 1 B) and the duration of time it
spends in this active state. We discuss below experi-
ments that suggest this putative engine may cycle rap-
idly (
 
 
 
10–100 s
 
 
 
1
 
).
Our ﬂuorescence resonance energy transfer (FRET)
and PLC activity measurements also show that the clus-
ter of basic residues on the JM domain can, when
bound to the membrane, electrostatically sequester
PIP
 
2
 
. Thus ErbB may function as a scaffolding protein
with its JM domain rapidly concentrating and releasing
PIP
 
2
 
 in the vicinity of PLC-
 
 
 
 and phophoinositide
3-kinase (PI3K), enzymes that are bound to the ErbB
COOH-terminal region and use PIP
 
2
 
 as a substrate.
 
MATERIALS AND METHODS
 
Materials
 
1-palmitoyl-2-oleoyl-
 
sn-
 
PS, 1-palmitoyl-2-oleoyl-
 
sn
 
-phosphatidyl-
choline (PC), 1-palmitoyl-2-oleoyl-
 
sn-
 
phosphatidylglycerol (PG),
and the ammonium salt of 
 
l
 
-
 
 
 
-phosphatidyl-
 
d
 
-myo-inositol 4,5-
bisphosphate (PIP
 
2
 
) were purchased from Avanti Polar Lipids.
Labeled [dioleoyl-1-
 
14
 
C]L-
 
 
 
-dioleoylphosphatidylcholine and
[
 
ethyl-
 
1,2-
 
3
 
H]
 
N
 
-ethylmaleimide (NEM) were from PerkinElmer
Life Sciences. 6-Acryloyl-2-dimethylaminonaphthalene (acryl-
odan), Alexa488, and Texas red were from Molecular Probes,
Inc. Bodipy-TMR-PIP
 
2
 
 was purchased from Echelon. Sphingosine
was from Sigma-Aldrich.
All peptides were obtained from American Peptide Co., Inc.
Each peptide was blocked with an acetyl group at its NH
 
2
 
 termi-
nus and an amide group at its COOH terminus. We performed
binding measurements with peptides corresponding to the re-
gions of ErbB receptors shown in Fig. S6 (available at http://
www.jgp.org/cgi/content/full/jgp.200509274/DC1); the pep-
tides had an extra Cys group at the NH
 
2
 
 terminus, which permit-
ted covalent attachment of either a radioactive (NEM) or ﬂuores-
cent (acrylodan for stop ﬂow, Texas red for FRET, Alexa488 for
FCS measurements) probes as described elsewhere (Wang et al.,
2002, and references therein). We used peptides without Cys for
the zeta potential and surface pressure measurements. Labeled
peptides were puriﬁed by high pressure liquid chromatography
and MALDI-time-of-ﬂight mass spectroscopy. We obtained simi-
lar results (see Fig. 4; Table I) with bovine brain (Sigma-Aldrich
and Calbiochem) and human brain (Calbiochem) calmodulin,
although different samples varied approximately twofold in their
afﬁnity for a given peptide.
We formed multilamellar vesicles (MLVs) for zeta potential
measurements, 100-nm-diameter large unilamellar vesicles
(LUVs) for FRET, FCS, and stop ﬂow ﬂuorescence measure-
ments, and 100-nm sucrose-loaded LUVs for centrifugation bind-
ing measurements, as described previously (Wang et al., 2002).
 
Methods
 
Measurements of Peptide Binding to LUVs.
 
We measured the
binding of [
 
3
 
H]NEM-labeled peptides to sucrose-loaded PC/PS
LUVs using a centrifugation technique described previously
(Wang et al., 2002; Gambhir et al., 2004). In brief, we mixed su-
crose-loaded LUVs and a trace concentration (
 
 
 
5 nM) of
[
 
3
 
H]NEM-labeled peptide, and then centrifuged the mixture at
100,000 
 
g
 
 for 1 h. We calculated the percentage of peptide
bound from counts of the radioactive peptide in the supernatant
and in the pellet.
 
Zeta Potential of MLVs.
 
We measured the electrophoretic mo-
bility (velocity/ﬁeld) of single MLVs and calculated the zeta po-
tential, the electrostatic potential at the hydrodynamic plane of
shear (
 
 
 
0.2 nm from the surface), using the Helmholtz-Smolu-
chowski equation (Wang et al., 2002, and references therein).
 
Surface Pressure Measurements.
 
We deposited a stock lipid–
chloroform solution onto the surface of a 15-ml aqueous solution
in a 5-cm-diameter Teﬂon trough with a magnetic stirrer at the
bottom. Once the chloroform had evaporated, we measured the
surface pressure of the monolayer using a square piece of ﬁlter
paper and a balance from Nima Technology Ltd. We then added
the peptide to the subphase and measured the change in surface
pressure as described previously (Wang et al., 2002).
 
FRET.
 
We monitored FRET between a Bodipy TMR label on PIP
 
2
 
and a Texas red label attached to membrane-bound ErbB1(645–
660) as described previously (Gambhir et al., 2004); the mem-
brane contained 69.7% PC, 30% PS, and 0.3% PIP
 
2
 
.
 
Circular Dichroism (CD) Spectroscopy.
 
We obtained the CD
spectrum of ErbB1(645–660) bound to isotropic bicelles on an
Olis DSM CD spectrometer (Olis Instruments) with a 0.2-mm
path-length cell. The bicelles were composed of a mixture of
DMPC, DMPG, and DHPC in a 10:3:13 molar ratio. The buffered
bicelle solution (20 mM sodium phosphate, pH 7.0) was 10%
(wt/vol) lipid and the peptide:lipid ratio was 1:100. Measure-
ments of a bicelle solution without peptide prepared in parallel
were subtracted as background. The corrected CD spectrum ex-
hibits the strong negative ellipticity at 200 nm characteristic of
random-coil structures.
 
Fluorescence Correlation Spectroscopy (FCS).
 
We used a Carl
Zeiss MicroImaging, Inc. Confocor II microscope to monitor the
binding of Alexa488-labeled ErbB1(645–660) to 2:1 PC/PS 100-
nm LUVs and to study the ability of Ca/CaM to remove the pep-
tide from the membrane. The experimental techniques were
similar to those described in detail in Rusu et al. (2004). In brief,
the correlation times of the peptide bound to 100-nm LUVs and
to Ca/CaM are 1,700 
 
 
 
s and 100 
 
 
 
s, respectively; hence we could
distinguish the two correlation times easily. We determined the
afﬁnity of Ca/CaM for the peptide by plotting the fraction of
membrane-bound peptide against the concentration of Ca/CaM
in the solution, as shown for experiments using the centrifuga-
tion technique (see Fig. 4).
 
Stop Flow Kinetics.
 
We made ﬂuorescence stop ﬂow kinetic
measurements to determine the rate at which Ca/CaM removes
membrane-bound acrylodan-labeled ErbB1(645–660) from PC/
PS vesicles; adding Ca/CaM increased the ﬂuorescence approxi-
mately fourfold as the peptide moved from vesicle to Ca/CaM.
Speciﬁcally, one solution contained 200 or 400 nM acrylodan-
labeled ErbB1(645–660) bound to 100-nm 85:14:1 PC/PS/NBD-PS
vesicles (100 
 
 
 
M accessible lipid; the 1% NBD-PS in these mem-
branes quenches the acrylodan ﬂuorescence), and the other solu-
tion contained 0.5, 1, 2, 4, or 7 
 
 
 
M CaM, and 50 
 
 
 
M CaCl
 
2
 
. Both
solutions contained 100 mM KCl buffered to pH 7.0 with 1 mM
MOPS. We measured the time constants of the exponential in-
crease in ﬂuorescence, 
 
 
 
, and determined the slope of 1/
 
 
 
 vs 
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[CaM]. This slope is equal to the transfer rate constant. The two
peptide concentrations produced identical time constants, as ex-
pected. We repeated the stop ﬂow measurements with vesicles
containing 10, 12, and 18% PS. The results and experimental de-
tails are similar to those shown in Fig. 7 of Arbuzova et al. (1997)
for a different basic/hydrophobic acrylodan-labeled peptide.
 
Calculation of Electrostatic Potentials.
 
We built atomic models
of the 2:1 PC/PS bilayer (Wang et al., 2002) and ErbB1(645–
660) in an extended conformation using the Insight Biopolymer
and Discover modules (Accelrys); the atomic radii and partial
charges assigned to the peptide were taken from the CHARMM
forceﬁeld. We solved the nonlinear Poisson-Boltzmann equation
for atomic models of these systems in 100 mM KCl. The resulting
potential maps, as well as the atomic coordinates for the pep-
tide/membrane/CaM models, were displayed using GRASP.
 
Online Supplemental Material
 
The supplemental material for this paper comprises eight ﬁgures
(available at http://www.jgp.org/cgi/content/full/jgp.200509274/
DC1). Fig. S1 shows how the binding of the ErbB1 JM peptide de-
pends on the mole fraction of acidic lipid in the membrane. Fig.
S2 shows FRET between the ErbB1 JM peptide and PIP2. Fig. S3
shows the effect of the ErbB1 JM peptide on PLC-catalyzed PIP2
hydrolysis. Fig. S4 shows an atomic model of membrane, ad-
sorbed ErbB1 JM peptide and calcium/calmodulin, and illus-
trates the predicted electrostatic potentials of the membrane and
molecules. Fig. S5 shows the electrostatic potential adjacent to a
complex of calmodulin and a peptide similar to the ErbB1 JM
domain. Fig. S6 shows ErbB family members share a common ba-
sic/hydrophobic JM region. Fig. S7 shows the kinase domains of
ErbB family members have a positively charged face in common.
Fig. S8 shows the patterns of ErbB1 phosphorylation predicted
by the model under different conditions.
 
RESULTS
 
ErbB1(645–660) Binds Strongly to Phospholipid Vesicles 
through Nonspeciﬁc Electrostatic Interactions
 
We ﬁrst tested the postulate that the ErbB1 reversible
membrane anchor region binds to the plasma mem-
brane by determining if a peptide corresponding to
this region, ErbB1(645–660), binds to phospholipid
vesicles. The data in Fig. 3 show this is indeed the case:
ErbB1(645–660) binds strongly to vesicles containing
physiological (15–30%) mole fractions of the monova-
lent acidic lipid PS. We describe the binding using Eq.
1 (Arbuzova et al., 2000):
(1)
where [P]
 
mem
 
/[P]
 
tot
 
 is fraction of peptide bound, [L]
 
acc
 
is the accessible lipid concentration (1/2 the total lipid
concentration because we add the peptide to pre-
formed vesicles), and K is the molar partition coefﬁ-
cient. Three characteristics of the binding indicate it is
due mainly to nonspeciﬁc electrostatic interactions: the
binding energy is independent of the chemical nature
of the monovalent acidic lipid, decreases markedly if
the salt concentration increases, and increases linearly
P [] mem P [] tot ⁄ KL [] acc 1K L [] acc + () ⁄ , =
(K increases exponentially) with the mole fraction of
acidic lipid; see Fig S1 (available at http://www.jgp.org/
cgi/content/full/jgp.200509274/DC1).
Is the binding strong enough to anchor this region of
ErbB1 to a plasma membrane, which typically contains
15–30% acidic phospholipid (Holthuis and Levine,
2005)? Our measurements (see online supplemental
material, available at http://www.jgp.org/cgi/content/
full/jgp.200509274/DC1) show that the peptide binds
strongly to membranes containing either monovalent PS
(104   K   106 M 1 for PC/PS vesicles with 15–30% PS)
or multivalent PIP2 (K   6   104 M 1 for 99:1 PC/PIP2
vesicles). Moreover, the adjacent transmembrane helix
of ErbB molecules tethers the basic region of the JM do-
main to the bilayer (Fig. 1), so it experiences a high ef-
fective lipid concentration, [lipid]eff   10 2 M. Extrapo-
lating our peptide binding results to the tethered 645–
660 region of ErbB1 suggests this region is bound to the
plasma membrane  99% of the time (ratio of bound/
free   K[lipid]eff   100). We used a peptide comprising
both the TM and the basic–hydrophobic cluster of the
JM domains, ErbB1(622–660), which has four additional
amino acids (RRRS) added at the NH2 terminus, to ob-
tain more direct evidence to support this conclusion. Re-
constitution of ErbB1(622–660) with a COOH-terminal
Texas red label into vesicles containing  1% PIP2 with a
Figure 3. Binding of ErbB1(645–660) to phospholipid vesicles.
Vesicles were formed from a mixture of the zwitterionic lipid PC
and the acidic lipid PS. 100 nm LUVS were formed from 2:1
PC/PS (ﬁlled circles) or 5:1 PC/PS (open circles); the external
aqueous solutions contained 100 mM KCl, 1 mM MOPS, pH 7.0.
The binding measurements were made with a low ( 4 nM) con-
centration of radiolabeled (NEM) peptide using a centrifugation
assay. The solid lines through the points illustrate the ﬁt of Eq. 1
to the data. The molar partition coefﬁcient, K (or apparent associ-
ation constant of the peptide with a lipid), is the reciprocal of the
lipid concentration that binds 50% of the peptide; the dotted line
indicates K    2    104 M  1 for 5:1 PC/PS vesicles. The bars
through the data points illustrate the SD of n   4 independent
experiments.46 Autoinhibition and Activation of the EGFR
Bodipy-TMR label produces strong FRET between the
ﬂuorophores (Sato, T., personal communication). The
simplest interpretation of this result, together with com-
plementary NMR data showing the TM helix breaks
close to the membrane interface, is that residues 645–
660 in the ErbB1(622–660) peptide are bound to the
bilayer.
ErbB1(645–660) Laterally Sequesters PIP2
When the 645–660 region of ErbB1 is bound to the bi-
layer component of the plasma membrane, it produces
a local positive electrostatic potential that will attract
multivalent acidic lipids, even when monovalent acidic
lipids are present in excess (see Fig. S4, available at
http://www.jgp.org/cgi/content/full/jgp.200509274/
DC1). FRET and PLC activity measurements demon-
strate directly that membrane-bound ErbB1(645–660)
laterally sequesters PIP2, even in membranes compris-
ing physiological levels of both PS and PIP2 (Figs. S2
and S3).
Biological Experiments Consistent with our Autoinhibition 
Hypothesis
A quantitative comparison of three results from earlier
experiments on cell membranes and data from pep-
tide/phospholipid vesicle studies indicate that electro-
static interactions can explain ErbB autoinhibition.
First, hyperosmotic shock stimulates tyrosine phosphor-
ylation of ErbB1 and ErbB2 in the absence of ligand
(King et al., 1989; Rodriguez et al., 2002). The model
predicts this effect because high salt should reduce the
electrostatic attraction of the JM   PTK domains for
the membrane; binding measurements show that in-
creasing the salt concentration threefold reduces ErbB1
(645–660) binding  500-fold (online supplemental
material, available at http://www.jgp.org/cgi/content/
full/jgp.200509274/DC1). Second, 1 mM Mn2  or 10
mM Mg2  activates ErbB1 in a broken cell prepara-
tion (Carpenter et al., 1979). Our model also predicts
this effect because these divalent cations bind to mem-
branes containing acidic lipids, reducing the magni-
tude of the negative electrostatic potential; binding
measurements show adding 1 mM Mn2  or 10 mM
Mg2  reduces binding of ErbB1(645–660) to 2:1 PC/PS
vesicles by  100-fold or  1,000-fold, respectively. Third,
2–5  M sphingosine, an amphipathic, membrane-per-
meable weak base, activates ErbB1 in WI-38 ﬁbroblasts,
provided the receptor is in an intact membrane (Davis
et al., 1988); in contrast, EGF can activate ErbB1 both in
membranes and in solubilized form. The model pre-
dicts that amphipathic weak bases should reduce the
negative charge on the inner leaﬂet of the bilayer and
thus its electrostatic attraction for the basic JM region;
our data demonstrate that 2  M sphingosine reverses
the charge (sign of the zeta potential, direction of the
electrophoretic movement) of a 2:1 PC/PS vesicle and
causes 75% of the ErbB1(645–660) peptide to desorb
from PC/PS vesicles (online supplemental material).
Ca/CaM Removes ErbB JM Peptides from 
Membranes Rapidly
The mechanism shown in Fig. 1 B, i.e., Ca/CaM binds
to the membrane anchor region and removes it and
the PTK domain to facilitate EGF-mediated activation,
is admittedly speculative, but peptide experiments pro-
vide evidence that it is feasible. We ﬁrst tested whether
Ca/CaM competes with phospholipid membranes for
binding of ErbB1(645–660); Fig. 4 shows peptide bind-
ing to 2:1 PC/PS vesicles in the presence of increasing
[Ca/CaM]. In the absence of Ca/CaM, 90% of the pep-
tide binds to the vesicles, as expected from both theo-
retical calculations (unpublished data; see Murray et
al., 2002, for methods) and the binding results in Fig.
3. The open circles in Fig. 4 illustrate the effect of in-
creasing [Ca/CaM]: adding 0.1  M Ca/CaM reduces
binding by  50% (total [CaM]    10–100   M in a
mammalian cell). Adding CaM in the absence of free
Ca2  does not affect ErbB1(645–660) binding to the
vesicles (ﬁlled circles). These data indicate that Ca/
CaM binds to ErbB1(645–660) with high afﬁnity (Kd  
10 nM), preventing the peptide from binding to a
Figure 4. Ca/CaM binds with high afﬁnity to ErbB1(645–660)
and prevents its association with lipid vesicles. The percent bound
peptide, present only at a trace concentration ( 5 nM), is plotted
as a function of the concentration of CaM in the presence (open
circles, [Ca2 ]free  20  M) or absence (ﬁlled circles) of Ca2 . The
total lipid concentration is 2   10 5 M and the solutions contain
100 mM KCl, 1 mM MOPS, pH 7.0, 100  M EGTA,  120  M
CaCl2. The solid curve illustrates the prediction of Eq. 2, taking the
association constant of the peptide with the membrane, K   106
M 1 (Fig. 3), and deducing the association constant of the peptide
with Ca/CaM, KCaM   108 M 1 from the ﬁt of Eq. 2 to the data.
The fraction of radioactively labeled peptide bound to the 100 nm
2:1 PC/PS large unilamellar vesicles (LUVs) was determined by a
centrifugation technique.McLaughlin et al. 47
phospholipid vesicle. We used a modiﬁed version of
Eq. 1 to describe the effect of Ca/CaM on ErbB1(645–
660) membrane binding, incorporating the assump-
tion that Ca/CaM and the membrane compete for the
peptide:
(2)
where K is the molar partition coefﬁcient of the pep-
tide onto the 2:1 PC/PS vesicles (106 M 1 from Fig. 3)
and KCaM is the association constant of the peptide with
Ca/CaM (KCaM   108 M 1 from the ﬁt of Eq. 2 to data
in Fig. 4).
We repeated the measurements shown in Fig. 4 us-
ing 3:1 rather than 2:1 PC/PS vesicles and obtained a
similar value for KCaM. We also used an independent
method, ﬂuorescence correlation spectroscopy (FCS),
to validate the centrifugation technique used to obtain
the measurements shown in Fig. 4. FCS measures the
correlation time (inversely proportional to diffusion
constant) of a ﬂuorescent label, in this case Alexa488
attached to ErbB1(645–660). The labeled peptide dif-
fuses slowly when bound to the large (100 nm) vesicles
and rapidly when bound to the smaller Ca/CaM; thus
we can determine the fraction of membrane-bound
peptide as a function of the concentration of Ca/CaM.
Both centrifugation and FCS measurements with
Alexa488-labeled ErbB1(645–660) indicate KCaM   107
M 1 (U. Golebiewska, personal communication; un-
published data). Thus, we conclude that the FCS mea-
surements validate the centrifugation technique. As ex-
pected from electrostatics, the negatively charged Alexa
probe decreases the afﬁnity of the peptide for Ca/CaM
(and vesicles)  10-fold.
Phosphorylation of Thr654 also decreases the afﬁn-
ity of ErbB1(645–660) for Ca/CaM. Experiments
similar to those shown in Fig. 4, but conducted with
an ErbB1(645–660) peptide with a phosphorylated
Thr654, show that phosphorylation reduces KCaM 20-
fold: removal of 50% of the phosphopeptide from the
vesicles requires 20-fold more Ca/CaM than shown in
Fig. 4 under similar conditions, i.e., when 90% of the
phosphopeptide is bound initially. Phosphorylation also
decreases the membrane binding of the peptide  10-
fold. These results agree well with previous measure-
ments showing that phosphorylation “drastically ham-
pers” (Martin-Nieto and Villalobo, 1998) or “totally in-
hibits” (Aifa et al., 2002) the ability of Ca/CaM to bind
to this region of ErbB1. The model shown in Fig. 1 thus
predicts that phosphorylation of Thr654 by PKC should
signiﬁcantly attenuate at least the early phase of ErbB1
autophosphorylation, a prediction consistent with ex-
periment (Couchet et al., 1984; Hunter et al., 1984;
Countaway et al., 1990; Welsh et al., 1991). However,
phosphorylation of Thr654 also produces a less robust
P [] mem P [] tot ⁄
KL [] acc 1K L [] acc KCaM Ca CaM ⁄ [] ++ () ⁄ ,
=
inhibition of ErbB1 autophosphorylation in model sys-
tems, such as A431 cell membranes (e.g., Couchet et al.,
1984), which must be due to some other phenomenon.
How rapidly can Ca/CaM remove the ErbB1 645–660
region from a plasma membrane? We approached this
question by making ﬂuorescence stop ﬂow measure-
ments to determine how rapidly Ca/CaM can remove
acrylodan-labeled ErbB1(645–660) from model mem-
branes that have a physiologically relevant fraction of
acidic lipid, i.e., 85:15 PC/PS vesicles. The vesicles had
1% NBD-PS to quench the ﬂuorescence. If   is the mea-
sured time constant for moving a peptide from a vesicle
to Ca/CaM, 1/  increases linearly from 3 s 1 to 30 s 1
as [Ca/CaM] increases to 5  M. Put another way, add-
ing 5  M Ca/CaM reduces the lifetime of the peptide
on the vesicles 10-fold, from  0.3 to 0.03 s. The trans-
fer rate constant, deﬁned as the slope of the (1/ ) vs.
[CaM] data, is 5   106 M 1s 1 for 85:15 PC/PS vesicles
and 5   107 M 1s 1 for 90:10 PC/PS vesicles, a value
close to the diffusion limited rate ( 108 M  1s 1) at
which Ca/CaM combines with other proteins in solu-
tion (online supplemental material, available at http://
www.jgp.org/cgi/content/full/jgp.200509274/DC1).
The kinetics results are perhaps surprising: the sim-
plest interpretation of our equilibrium measurements
(Fig. 4) is that Ca/CaM acts as a passive peptide buffer.
That is, adding it to a solution containing peptides
bound to vesicles should merely decrease the equilib-
rium concentration of free peptide in the bulk aqueous
phase, allowing peptide to desorb from the vesicles at
its spontaneous rate until a new equilibrium is attained.
The stop ﬂow measurements, however, reveal that Ca/
CaM increases the rate at which ErbB1(645–660) des-
orbs from the vesicles, presumably by ripping the pep-
tide directly from the surface; we have discussed this
mechanism elsewhere (Arbuzova et al., 1997, 1998).
Figs. S4 and S5 (available at http://www.jgp.org/cgi/
content/full/jgp.200509274/DC1) show, respectively,
calculations of the electrostatic potential for an atomic
model of Ca/CaM approaching a membrane-bound
ErbB1(645–660) and calculations of the electrostatic
potential adjacent to Ca/CaM bound to a basic pep-
tide. The atomic models illustrate how electrostatic at-
traction may guide Ca/CaM (net charge z    16) to
the membrane-associated JM region (z     8), how
electrostatic interactions may help rip the peptide from
the surface (Arbuzova et al., 1998), and how the Ca/
CaM-JM region complex (z     8) may then be re-
pelled from the membrane surface.
We performed binding measurements similar to
those shown in Figs. 3 and 4 with peptides correspond-
ing to the reversible membrane anchor region of other
members of the ErbB family. The basic/hydrophobic
nature of this region is moderately conserved (Fig.
S6, available at http://www.jgp.org/cgi/content/full/48 Autoinhibition and Activation of the EGFR
jgp.200509274/DC1), and Table I shows they all bind
to both membranes and Ca/CaM, suggesting that the
electrostatic engine model may apply to activation of all
four molecules. Moreover, the PTK core regions of all
ErbB family members share a positively charged face
(Fig. S7).
CaM Inhibitors Reduce the Initial Rate of EGF-mediated 
Autophosphorylation in Cos1 Cells
A key prediction of the mechanism shown in Fig. 1 B is
that exposing cells to membrane-permeable CaM in-
hibitors such as W-7 should inhibit the initial rate of
EGF-mediated ErbB1 autophosphorylation. Accord-
ing to our model, CaM inhibitors should affect auto-
phosphorylation only for a short time ( 15 min) after
EGF stimulation because the concomitant increase in
cytoplasmic Ca2  to values that activate CaM signiﬁ-
cantly is only transient. For example, Hughes et al.
(1991) reported the intracellular [Ca2 ] in A431 cells
increases to 600 nM in 5 min, but falls to 150 nM by 15
min. Nojiri and Hoek (2000) show the intracellular
[Ca2 ] in hepatocytes increases to 450 nM in 1–2 min,
and then falls to 150 nM in the next 2–3 min. Fig. 5
shows treating Cos1 cells with W-7 produces dose-depen-
dent  inhibition of ErbB1 tyrosine phosphorylation
measured 10 min after addition of EGF; the concentra-
tion range used, 20–50  M, was selected on the basis
of the inhibitor’s afﬁnity for Ca/CaM (Osawa et al.,
1998). EGF-stimulated ErbB1 autophosphorylation is
maximal  10 min after adding EGF to Cos1 cells un-
der our conditions (unpublished data). Recent de-
tailed studies in two other cell types showed that the
CaM inhibitors W-7, W-12, and W-13 inhibit the ini-
tial peak of ErbB1 autophosphorylation, but not the
steady-state value observed for times  20 min (Li et
al., 2004a), as expected from our model. Li et al.
(2004a) report an important control experiment: W-7,
W-12, and W-13 do not inhibit the tyrosine kinase activ-
ity of a puriﬁed ErbB1 preparation.
DISCUSSION
Membrane Binding of ErbB Intracellular Regions and 
Postulated Role of Ca/CaM
Our peptide experiments and/or theoretical calcula-
tions support the hypothesis that both the JM region
and PTK domain of ErbB family members bind electro-
statically to the inner leaﬂet of the plasma membrane.
If our postulate that this binding produces autoinhibi-
tion is correct, factors that reduce these electrostatic in-
teractions should stimulate cellular ErbB autophosphor-
ylation in the absence of ligand. Speciﬁcally, we postu-
late that autophosphorylation depends on both the
rate at which ErbB monomers collide in the plasma
membrane and the probability the JM   PTK domain
is in a membrane-dissociated active conformation. Our
model membrane experiments allowed us to measure
quantitatively the levels of salt, divalent cations, or the
amphipathic weak base sphingosine required to disen-
gage a peptide corresponding to the membrane an-
chor region from a lipid bilayer; when we compared
the values to those reported for ligand-independent ac-
tivation of ErbB1 in cells or broken membrane prepa-
rations (Carpenter et al., 1979; Davis et al., 1988; King
et al., 1989), there was quantitative agreement in each
case. Thus the mechanism illustrated in Fig. 1 A pro-
vides a plausible and experimentally testable explana-
tion for autoinhibition, but it does not address the spe-
ciﬁc mechanism by which membrane binding inhibits
tyrosine kinase activity. Possible mechanisms could in-
clude restricted rotation of the PTK domain that pre-
vents interaction of the catalytic site and substrate, or
structural effects on the activation loop within the PTK
domain (Stamos et al., 2002; Wood et al., 2004); several
recent reviews discuss autoinhibitory mechanisms for
receptor tyrosine kinases in some detail (Jorissen et al.,
2003; Schlessinger, 2003; Hubbard, 2004).
TABLE I
Affinity of Peptides for Membranes and Ca/CaM
Peptide
Molar Partition 
Coefficient (K)
Ca/CaM Association 
Constant (KCaM)
ErbB1(645–660) 1   106 M 1 1   108 M 1
ErbB2(676–692) 5   105 M 1 6   107 M 1
ErbB3(667–683) 2   104 M 1 3   106 M 1
ErbB4(676–692) 2   105 M 1 2   107 M 1
The centrifugation assay was used to measure the binding of ErbB peptides
to 2:1 PC/PS LUVs (numbers correspond to position in sequence of native
protein; see Fig. S6, available at http://www.jgp.org/cgi/content/full/
jgp.200509274/DC1, for sequences). The values of K and KCaM were
determined from Eqs. 1 and 2, respectively. The solutions contained 100
mM KCl, 1 mM MOPS, pH 7; solutions used in Ca/CaM binding
experiments also contained 100  M EGTA   120  M Ca2 .
Figure 5. The calmodulin inhibitor W7 inhibits the EGF-medi-
ated autophosphorylation of the ErbB1 receptor. Cos1 cells were
treated with 20–50  M W-7 for 30 min, and then exposed to 100
ng/ml ( 20 nM) EGF for 10 min. The cells were lysed and treated
with rabbit anti-ErbB1 to immune precipitate the receptor.
Western blots were performed on the immunoprecipitates using
the murine antiphosphotyrosine monoclonal antibody 4G10, (top
panel). Reprobing of the same blot with a rat anti-ErbB1 monoclo-
nal antibody (bottom panel) demonstrated that W-7 treatment did
not affect receptor levels during the time frame of the experiment.McLaughlin et al. 49
Our data show that Ca/CaM binds strongly to pep-
tides corresponding to the membrane anchor region of
ErbB1 (Fig. 4) and the corresponding JM regions in
other ErbB family members (Table I). The results agree
qualitatively with previous reports that Ca/CaM binds
strongly to these regions of ErbB1 (Martin-Nieto and
Villalobo, 1998; Li et al., 2004a) and ErbB2 (Li et al.,
2004b). We note that Martin-Nieto and Villalobo (1998)
reported KCaM   3   106 M 1, but their Ca/CaM bind-
ing measurements employed 0.3   10 6 M of a GST-
ErbB1(645–660) construct; thus we interpret their mea-
surements to mean KCaM   3   106 M 1, which agrees
with our estimate. These data suggest that the activation
mechanism illustrated in Fig. 1 B is feasible and could
enhance the activation produced by ligand-induced
dimerization, which presumably acts through a local
concentration effect (Schlessinger, 2000).
The Electrostatic Engine Mechanism in ErbB Activation
Our model suggests the following process for EGF-
mediated trans autophosphorylation. When EGF-stimu-
lated dimerization occurs, the level of intracellular
[Ca2 ], and thus Ca/CaM, is initially low. The ErbB JM  
PTK regions, however, move off the membrane sponta-
neously, albeit at a low rate (e.g., stop ﬂow measure-
ments demonstrate acrylodan-labeled ErbB1(645–660)
moves off a 85:15 PC/PS vesicle at a rate of 3 s 1). The
small fraction of receptors with dissociated JM   PTK
domains will produce a low level of trans autophosphor-
ylation even in the absence of Ca/CaM. When PLC- 
binds to a phosphorylated ErbB and hydrolyzes its sub-
strate PIP2, it produces IP3, which in turn releases Ca2 
from internal stores, increasing the concentration of
Ca/CaM (for review see Jorissen et al., 2003). Our mea-
surements show that Ca/CaM increases both the rate at
which peptides corresponding to the ErbB1 membrane
anchor region leave the membrane and the fraction of
membrane-dissociated peptide (Fig. 4). As the JM and
kinase domains of an ErbB move off the membrane,
the latter becomes catalytically active in our model, as
illustrated for one member of the ErbB1 dimer in Fig. 1
B. Thus we postulate that Ca/CaM drives a positive
feedback mechanism that produces maximal activation
of ErbB. The mechanism functions only when the local
[Ca2 ] is sufﬁciently elevated to provide a source of
Ca/CaM; intracellular [Ca2 ] measurements indicate
this occurs only for times  15 min after exposure to
EGF (Hughes et al., 1991; Nojiri and Hoek, 2000). This
electrostatic engine model predicts that CaM inhibitors
(or agents that increase the intracellular Ca2  buffering
capacity) will diminish the transient increase in trans
autophosphorylation observed within 15 min of EGF
stimulation, but have little effect on the steady-state
level of activity measured at later times. CaM inhibitors
do indeed inhibit peak level of EGF-mediated ErbB1
autophosphorylation in Cos1 (Fig. 5) and two other
cell types (Li et al., 2004a), but have no effect on the
steady-state level of autophosphorylation (Li et al.,
2004a). Agents that deplete intracellular stores of Ca2 ,
such as thapsigargin, should and do inhibit receptor
autophosphorylation in A431 cells measured 5 min af-
ter addition of EGF (Friedman et al., 1989).
Less direct evidence in support of this hypothesis
comes from studies of Ca2 -induced transactivation of
ErbB1 (i.e., activation that occurs without addition of a
ligand that binds directly to ErbB1). Transactivation
can occur in response to activation of Gq-coupled re-
ceptors, opening of ion channels selective for Ca2 , or
addition of Ca2  ionophores (for review see Zwick et
al., 1999). Much recent work on the transactivation of
ErbB1 has focused on the unique triple-membrane-
passing signal (Prenzel et al., 1999; for reviews see
Gschwind et al., 2001; Blobel, 2005), but our model
provides a clue as to how an increase in [Ca2 ] and Ca/
CaM could initiate this interesting phenomenon. If
Ca2  helps initiate transactivation by the mechanism
shown in Fig. 1 B, both CaM inhibitors and Ca2  buff-
ers should inhibit transactivation. Murasawa et al.
(1998) reported both the CaM inhibitor W-7 and the
Ca2  buffer BAPTA-AM inhibit angiotensin II–stimu-
lated ErbB1 transactivation in cardiac ﬁbroblasts.
Rigorous testing of the model will require extensive
molecular and cell biological experiments as well as
biophysical measurements on larger peptides corre-
sponding to the ErbB TM   JM domains reconstituted
into vesicles, which are in progress. If additional work
supports our postulate that Ca/CaM may act in concert
with dimerization to stimulate ErbB1 activation, the
model shown in Fig. 1 can probably be extrapolated to
the ErbB2 and ErbB4 (Carpenter, 2003) family mem-
bers: peptides corresponding to their JM regions also
bind with high afﬁnity to both membranes and Ca/
CaM (Table I).
ErbB as a Scaffolding Protein
Our model also suggests a new and potentially impor-
tant function for ErbB in signal transduction. Binding
of the reversible membrane anchor region to the
negatively charged membrane should produce a local
positive potential (see Fig. S4, available at http://www.
jgp.org/cgi/content/full/jgp.200509274/DC1) that acts
as a basin of attraction for multivalent acidic lipids such
as PIP2. FRET and PLC hydrolysis experiments show
that ErbB1(645–660) laterally sequesters PIP2, even
when the membrane includes a physiologically rele-
vant 100-fold excess of monovalent acidic lipids (Figs.
S2 and S3). PIP2 is the substrate of PLC-  and PI3 kinase,
enzymes that bind to the phosphorylated COOH-termi-
nal regions of ErbB family members (Schlessinger,
2000). Thus a corollary of our hypothesis is that ErbB50 Autoinhibition and Activation of the EGFR
family members act as scaffolding proteins (Wong and
Scott, 2004), binding both enzymes and their substrate.
PLC cannot hydrolyze PIP2 sequestered by peptides cor-
responding to the ErbB JM basic cluster, however (Fig.
S3); PIP2 must ﬁrst be released from the basic cluster.
How rapidly can Ca/CaM bind to the JM region and
release the electrostatically sequestered PIP2? Our stop
ﬂow experiments reveal that 2  M Ca/CaM can re-
move acrylodan-labeled ErbB1(645–660) peptides
from PC/PS vesicles at rates of 10 and 100 s 1 for vesi-
cles containing 15 and 10% PS, respectively. It is difﬁ-
cult to extrapolate these results using a model system to
a living cell for several reasons. For example, ErbB1
may be in noncaveolar cholesterol- and PIP2-enriched
“rafts” that have a different lipid composition than the
bulk plasma membrane (e.g., Chen and Resh, 2002;
Roepstorff et al., 2002; Westhover et al., 2003; Simons
and Vaz, 2004, and references therein). We can state
that if the Ca/CaM level rises to  1  M in a cell, the
maximum (diffusion limited) rate at which Ca/CaM
could bind to the 645–660 JM region of ErbB1 and rip
it off the plasma membrane is  100 s 1.
How long will the Ca/CaM remain bound to the JM
region? The lifetime of Ca/CaM bound to a solubilized
ErbB1 molecule is probably  1 s (KCaM/kon   108 M 1/
108 M 1s 1), but theoretical considerations suggest the
lifetime of Ca/CaM bound to ErbB1 in a membrane
will decrease signiﬁcantly (possibly to 0.01 s) as the
mole fraction of acidic lipid in the membrane in-
creases. This is because the acidic lipids repel the nega-
tively charged Ca/CaM bound to the JM region.
Thus the electrostatic engine shown in Fig. 1 (A and
B) could cycle 10–100 times a second when the [Ca/
CaM] increases to  1  M. Even if the JM region re-
mains bound to the bilayer for only  0.01 s, this pro-
vides more than sufﬁcient time, t, for PIP2 to equilibrate
with the basic cluster through diffusion (from the Ein-
stein relation, t   x2/4D, where x is the distance PIP2
must diffuse in the plasma membrane and D is its diffu-
sion constant). FCS measurements show that the diffu-
sion constant of Bodipy-PIP2 in a ﬂuid phase PC phos-
pholipid membrane has the expected value of D   3  
10 8 cm2s 1 (Golebiewska, U., personal communica-
tion). In a plasma membrane, D could be 10-fold lower
because cholesterol increases the viscosity, and as much
as 90% of the PIP2 could be sequestered such that x  
distance between PIP2 free to diffuse   30 nm; even un-
der these conditions the diffusion time is only  0.001 s.
The maximal rate at which PLCs can hydrolyze PIP2 is
 102 s 1, so the JM region of ErbB can potentially cycle
on and off the membrane at a frequency that could fa-
cilitate the hydrolysis of PIP2 by an adjacent PLC .
One caveat concerning this electrostatic engine
mechanism: the free [Ca/CaM] in cytoplasm may be
signiﬁcantly lower than the total cellular [CaM] of 10–
100  M. Recent measurements suggest that much of
the Ca/CaM in cells may be bound to target proteins
(Persechini and Stemmer, 2002; Black et al., 2004; Kim
et al., 2004; Rakhilin et al., 2004).
Predictions of the Model
Fig. S8 (available at http://www.jgp.org/cgi/content/
full/jgp.200509274/DC1) illustrates how the model
shown in Fig. 1 can be used to predict the time course
of ErbB1 trans autophosphorylation after stimulation
by EGF. For simplicity, we assume that only three fac-
tors affect phosphorylation: ligand-induced dimeriza-
tion, which increases phosphorylation by a local con-
centration effect; phosphatases, which remove phos-
phates from ErbB1; and the calmodulin-dependent
positive feedback mechanism shown in Fig. 1, which
operates only when intracellular [Ca2 ] is elevated.
The plots show the predicted percent trans autophos-
phorylation as a function of time after addition of EGF
in three different cases: permeabilized cells lacking
both CaM and phosphatases, cells exposed to CaM in-
hibitors, and normal cells. Recent experimental results
appear to agree well with the predictions. We stress,
however, that the calculations in Fig. S8 represent a
highly oversimpliﬁed scheme; for example, we make no
attempt to incorporate the well documented endocyto-
sis of activated ErbB1 and PLC- 1 (Matsuda et al., 2001;
Wang et al., 2001; Wang and Wang, 2003). Endocytosis
has been considered quantitatively in models for ErbB
family activation by Lauffenburger and others (e.g.,
Wiley et al., 2003; Hendriks et al., 2005). We also ac-
knowledge that other, more complex, quantitative
models for short term signaling by ErbB1 (Kholodenko
et al., 1999; Moehren et al., 2002) can account for the
maximum in ErbB1 autophosphorylation by a different
mechanism than the one we invoke in Fig. 1. The ad-
vantages of formulating quantitative models of signal
transduction phenomena are discussed in a recent
commentary entitled “Why biophysicists make models”
(Shapiro, 2004) and in Papin et al. (2005). In our view,
the main advantage of these models (e.g., our Fig. 1;
Kholodenko et al., 1999; Moehren et al., 2002; Wiley et
al., 2003; Landau et al., 2004; Hendriks et al., 2005), is
that they make quantitative predictions and can thus be
easily falsiﬁed or modiﬁed by future experiments.
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